#Warsaw #Poland #mRNA #ExploRNA #Łukasiewicz

Strategic Partnership to Enhance mRNA Cap Manufacturing

In a significant move to bolster the biopharmaceutical landscape, ExploRNA Therapeutics has announced a strategic partnership with the Łukasiewicz Research Network – Industrial Chemistry Institute (Łukasiewicz - IChP). This collaboration aims to advance the GMP (Good Manufacturing Practice) production of next-generation mRNA cap analogs, which are critical components in the manufacturing of mRNA therapies and vaccines.

The Importance of mRNA Capping Technology

Both organizations recognize that as mRNA technology continues to revolutionize healthcare, the demand for high-quality, scalable components has become increasingly critical. Co-transcriptional capping is a pivotal stage in mRNA manufacturing, directly influencing the yield, quality, and efficiency of the final drug product. With this partnership, ExploRNA is set to deliver its proprietary cap analogs, including the innovative AvantCap Q1 technology, under stringent GMP standards. This not only secures a stable supply of essential raw materials for clinical-stage mRNA therapeutics but also caters to the growing needs of the biopharmaceutical industry.

Insights from Leadership

Prof. Jacek Jemielity, CEO of ExploRNA Therapeutics, expressed enthusiasm about the partnership, stating: "This collaboration with Łukasiewicz - IChP marks a critical milestone in our growth trajectory. Securing a reliable, high-quality GMP manufacturing partner is an important development step for ExploRNA." He emphasized that this partnership would validate the scalability of their synthesis processes and facilitate a smooth transition from laboratory developments to life-saving clinical applications.

The Impact on Biotech and Pharmaceutical Industries

The production of GMP-grade materials is an essential aspect of ExploRNA's commercial strategy, allowing them to support a range of biotech and pharmaceutical developers from early-stage research to late-stage clinical trials and commercialization. The collaboration with Łukasiewicz - IChP, noted for its expertise in chemical synthesis and production scaling, ensures that ExploRNA can meet the increasing demand for high-grade cap analogs, enabling its partners to advance their clinical programs efficiently.

This partnership not only underscores the transformative potential of mRNA technology but also highlights the commitment of both organizations to pioneering advancements in genetic medicines. The ability to manufacture and provide high-quality mRNA capping components will play a vital role in enhancing mRNA translational efficiency, ultimately leading to the development of effective treatment options for patients.

About the Companies

ExploRNA Therapeutics specializes in developing cutting-edge mRNA capping technologies and platform solutions. Their innovative approach enhances the translational efficiency of mRNA, thus paving the way for the next generation of genetic medicines.

On the other hand, the Łukasiewicz Research Network – Industrial Chemistry Institute is a prominent Polish research and development center. They focus on chemical synthesis, process engineering, and scaling up production for the pharmaceutical and advanced chemical sectors. In bringing together their expertise, both organizations are poised to significantly impact the field of mRNA therapeutics.

As the biopharmaceutical landscape evolves, partnerships such as this one between ExploRNA Therapeutics and Łukasiewicz - IChP highlight an exciting future in medical advancements, potentially changing the way we approach treatment for various diseases through innovative mRNA technologies.